Gastrointestinal toxicities following radiation therapy for localized prostate cancer.

• DOI: 10.1200/jco.2011.29.7_suppl.64
• Publication Date: 2017-02-23T18:54:21Z
• Authors: G. L. Lu-Yao; S. Kim; D. Moore; W. Shih; Y. Lin; S. Shen; H. Li; M. Dolan; Y. Shao
• Keywords: Hormonal Therapy

64 Background: Radiation therapy (RAD) is commonly employed to treat localized prostate cancer; however, representative data regarding treatment related toxicities compared conservative management (CM) sparse. Methods: We performed a population-based cohort study, using Medicare claims linked the Surveillance, Epidemiology, and End Results data, evaluate gastrointestinal (GI) in men aged 65-85 years treated with either primary RAD or CM for T1-T2 cancer diagnosed 1992-2005. In this only GI requiring interventional procedures occurring after 6 months of diagnosis were included. Competing risk models used following covariates: year diagnosis, comorbidity, age, tumor stage, grade, hormone use within 1 region, race, poverty marital status. Results: Among 41,859 patients 28,021 received radiation therapy, 19,287 external beam (EBRT) alone, 5,138 brachytherapy alone. The most common toxicity was bleeding ulceration. rates 6.1% 3D-conformal (3D-CRT), 2.8% intensity modulated (IMRT), 2.6% brachytherapy, 8.2% proton 1.1% patients. multivariate models, group associated higher hazard (hazard ratio [HR] 4.68; 95% CI, 3, 93-5.58) than CM. Comparing 3D-CRT, (HR 0.62; 0.51-0.75) IMRT 0.67; 0.55-0.82) are lower toxicities, while 2.15; 1.45-3.17). Conclusions: different modalities protons highest followed by IMRT, brachytherapy. increased may reflect learning curve early years. No significant financial relationships disclose.